Kissei Pharmaceutical has been granted a patent for methods to treat endometriosis by administering a gonadotropin-releasing hormone (GnRH) antagonist. The treatment approach is tailored based on the patient’s levels of anti-Müllerian hormone (AMH) or ß17-estradiol (E2) to alleviate associated pain. GlobalData’s report on Kissei Pharmaceutical gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Kissei Pharmaceutical, Cancer treatment biomarkers was a key innovation area identified from patents. Kissei Pharmaceutical's grant share as of June 2024 was 43%. Grant share is based on the ratio of number of grants to total number of patents.
Method for treating endometriosis with gnrh antagonist
The granted patent US11980621B2 outlines methods for treating endometriosis and alleviating associated pain in female patients. Central to these methods is the administration of a specific compound represented by formula (II). The claims detail various approaches, including the reduction of key hormones such as ß17-estradiol, follicle-stimulating hormone, and luteinizing hormone. The compound can be administered orally, with a preference for once-daily dosing. Additionally, the patent includes provisions for add-back therapy, which may involve the administration of estrogen, specifically ß17-estradiol, and/or progestin, such as norethindrone acetate, to mitigate potential side effects of the primary treatment.
Further claims specify the formulation of the compound, indicating that it may be provided as a choline salt. The add-back therapy is also described in detail, with specific dosages suggested for both ß17-estradiol (approximately 1.0 mg per day) and norethindrone acetate (approximately 0.5 mg per day). The patent also encompasses the creation of kits containing the compound represented by formula (II), which may facilitate its administration and enhance treatment compliance. Overall, the patent presents a comprehensive approach to managing endometriosis through targeted hormonal intervention and supportive therapies.
To know more about GlobalData’s detailed insights on Kissei Pharmaceutical, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
